New Prostate Cancer Treatment Approved

4/30/2010
The FDA has approved Dendreon’s Provenge (sipuleucel-T) for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment. Provenge is an autologous cellular immunotherapy that stimulates the patient’s own immune system to fight the disease. Provenge is administered intravenously in a 3-dose schedule given at approximately 2-week intervals.
Clin-eguide™ is an online clinical decision support tool that provides the most accurate evidence-based information for health care providers in the clinical setting. It integrates trusted content from Ovid, Facts & Comparisons®, and Lippincott Williams and Wilkins, as well as other premier publishers.